Last 25 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -40.80 | — | — | — | — | — | — | 841.59 | — | 5.84 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 6.09 | 2.24 | 2.27 | 6.78 | 5.30 | 3.57 | 3.01 | 2.90 | 0.98 | 0.82 | 0.94 | 0.91 | 0.91 | 1.39 | 0.93 | 1.21 | 1.74 | 1.13 | 1.67 | 2.52 | 4.36 |
| — | -37.3% | -24.6% | +134.3% | +439.4% | +333.5% | +219.3% | +217.9% | +7.4% | -40.8% | +1.2% | -24.7% | -47.4% | +23.7% | -44.3% | -51.9% | -60.1% | -52.7% | +14.2% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | 5.23 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | -1.14 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | 553.04 | — | -1.26 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.9% | -0.8% | -5.3% | -8.8% | -6.1% | -9.7% | -5.2% | 0.2% | -13.3% | 3.9% | -9.8% | -26.7% | -21.3% | -17.5% | -20.6% | -21.7% | -31.2% | -27.7% | -34.9% | -28.3% | -13.9% |
| — | +91.8% | -3.0% | -5739.5% | +54.1% | -349.8% | +47.0% | +100.6% | +37.7% | +122.3% | +52.4% | -22.8% | +31.6% | +36.8% | +41.1% | +23.3% | -124.7% | -85.1% | -202.6% | +41.1% | +86.6% | |
| ROA | -27.0% | -0.8% | -5.3% | -8.6% | -6.0% | -9.6% | -5.1% | 0.2% | -12.5% | 3.6% | -8.6% | -24.5% | -19.9% | -15.8% | -19.0% | -19.8% | -28.3% | -25.8% | -33.0% | -27.4% | -13.6% |
| — | +91.8% | -2.7% | -5712.0% | +52.2% | -368.1% | +40.0% | +100.6% | +37.3% | +122.7% | +55.1% | -23.8% | +29.7% | +38.8% | +42.3% | +27.9% | -108.7% | -75.3% | -191.2% | +38.0% | +70.3% | |
| ROIC | — | — | — | — | — | -608.6% | -1468.7% | -5043.6% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | — | — | — |
| — | -92.2% | -91.1% | -62.8% | -92.9% | +18.4% | -51.1% | -65.1% | +92.8% | -80.6% | -49.5% | -20.3% | -16.0% | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.06 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 36.10 | 121.97 | 81.48 | 57.37 | 36.10 | 86.56 | 88.27 | 126.15 | 11.32 | 35.08 | 7.69 | 8.01 | 24.26 | 11.62 | 9.83 | 21.64 | 8.11 | 22.88 | 11.72 | 31.48 | 31.38 |
| — | +40.9% | -7.7% | -54.5% | +218.8% | +146.8% | +1048.4% | +1475.6% | -53.3% | +201.9% | -21.8% | -63.0% | +198.9% | -49.2% | -16.1% | -31.2% | -74.1% | -66.7% | -81.4% | +37.6% | +439.3% | |
| Quick Ratio | 36.10 | 121.97 | 81.48 | 57.37 | 36.10 | 86.56 | 88.27 | 126.15 | 11.32 | 35.08 | 7.69 | 8.01 | 24.26 | 11.62 | 9.83 | 21.64 | 8.11 | 22.88 | 11.72 | 31.48 | 31.38 |
| — | +40.9% | -7.7% | -54.5% | +218.8% | +146.8% | +1048.4% | +1475.6% | -53.3% | +201.9% | -21.8% | -63.0% | +198.9% | -49.2% | -16.1% | -31.2% | -74.1% | -66.7% | -81.4% | +37.6% | +439.3% | |
| Interest Coverage | — | -2811.00 | -1900.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DRUG stock.
Bright Minds Biosciences Inc.'s current P/E is -40.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bright Minds Biosciences Inc.'s business trajectory between earnings reports.